证券代码：603880 证券简称：ST南卫 公告编号：2024-024 江苏南方卫材医药股份有限公司 涉及诉讼的结果公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 是否会对上市公司损益产生负面影响：针对该诉讼事项，江苏南方卫材医药 股份有限公司（以下简称"南卫股份""公司"）前期对466万涉诉往来款已计提 坏账准备459.31万元，截至目前共执行到7.57万元,待发现被执行人有可供执行财 产后，公司将向法院申请恢复执行。本次公告的诉讼结果预计对公司本期利润或期 后利润等无重大影响。最终会计处理及影响金额须以注册会计师审计确认后的结果 为准，敬请投资者注意投资风险。 因被执行人未履行生效法律文书确定的义务，公司向法院申请执行，法院在执 行过程中，共执行到7.57万元，法院查询被执行人名下银行账户、车辆及房产等信 息，无合适财产可供执行，法院已限制被执行人高消费，期限为无期，现被执行人 无其他合适财产可供执行，法院出具（2023）苏0412执恢882号执行裁定书，裁定 如下： 终结本院作出的(2021) ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 江苏南方卫材医药股份有限公司（以下简称"南卫股份"或"公司"）于2024年4 月19日收到上海证券交易所（以下简称"上交所"）出具的《关于江苏南方卫材医药 股份有限公司2023年度报告的信息披露监管问询函》（上证公函【2024】0332号）（以 下简称《问询函》），要求公司在10个交易日内针对《问询函》相关问题进行回复， 详见公司于2024年4月20日在上交所网站披露的《南卫股份收到上海证券交易所关于公 司2023年度报告的信息披露监管问询函的公告》（公告编号：2024-019）。 公司收到《问询函》后高度重视，积极组织各方对《问询函》中涉及的问题进行 逐项落实、回复。由于《问询函》中个别事项所涉及的数据、内容较多，汇总与整理 工作量较大，为确保回复内容的准确和完整，公司申请延期回复《问询函》，详见公 司2024年5月9日披露的《南卫股份关于延期回复上海证券交易所对公司2023年度报告 信息披露监管问询函的公告》（公告编号：2024-022）。鉴于部分问题仍需完善和补 充，为确保 ...

江苏南方卫材医药股份有限公司（以下简称"南卫股份"或"公司"）于2024年4 月19日收到上海证券交易所（以下简称"上交所"）出具的《关于江苏南方卫材医药 股份有限公司2023年度报告的信息披露监管问询函》（上证公函【2024】0332号）（以 下简称《问询函》），要求公司在10个交易日内针对《问询函》相关问题进行回复， 详见公司于2024年4月20日在上交所网站披露的《南卫股份收到上海证券交易所关于公 司2023年度报告的信息披露监管问询函的公告》（公告编号：2024-019）。 公司收到《问询函》后高度重视，积极组织各方对《问询函》中涉及的问题进行 逐项落实、回复。由于《问询函》中个别事项所涉及的数据、内容较多，汇总与整理 工作量较大，为确保回复内容的准确和完整，经向上交所申请，公司决定延期回复《问 询函》，延期时间不超过5个交易日，延期回复期间，公司将继续积极推进《问询函》 的回复工作，尽快完成《问询函》回复并及时履行信息披露义务。由此给投资者带来 的不便，敬请谅解。 有关信息以公司在上交所网站及指定信息披露媒体发布的公告为准，敬请广大投 资者关注公司公告，注意投资风险。 证券代码：603880 证券简 ...

Financial Performance - The company's operating revenue for Q1 2024 was ¥139,180,514.20, representing a decrease of 38.45% compared to the same period last year[5]. - The net profit attributable to shareholders was ¥1,745,086.17, down 74.82% year-on-year[5]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥553,290.70, a decline of 91.48% compared to the previous year[5]. - Basic earnings per share were ¥0.006, down 75.00% from the same period last year[5]. - Net profit for Q1 2024 was ¥1,752,439.19, a decline of 74.7% from ¥6,911,204.99 in Q1 2023[18]. - Operating profit for Q1 2024 was ¥992,605.52, a decrease of 87.5% compared to ¥7,919,872.69 in Q1 2023[18]. - Total operating revenue for Q1 2024 was ¥139,180,514.20, a decrease of 38.5% compared to ¥226,130,904.54 in Q1 2023[17]. - Total operating costs for Q1 2024 were ¥143,955,213.47, down 36.5% from ¥226,511,378.39 in Q1 2023[17]. - Research and development expenses for Q1 2024 were ¥6,652,533.16, a decrease of 20% from ¥8,313,881.01 in Q1 2023[17]. Cash Flow and Assets - The net cash flow from operating activities was -¥8,293,570.72, a decrease of 140.27% year-on-year[5]. - Cash flow from operating activities for Q1 2024 was negative at -¥8,293,570.72, compared to positive cash flow of ¥20,595,515.00 in Q1 2023[20]. - Cash and cash equivalents decreased significantly to ¥54,469,157.35 from ¥95,672,928.04, a decline of approximately 43.1%[13]. - Cash and cash equivalents at the end of Q1 2024 were ¥17,393,676.52, down from ¥142,900,250.05 at the end of Q1 2023[21]. - The company's current assets totaled ¥547,452,775.31, down from ¥569,536,332.52, indicating a decrease of about 3.7%[13]. - The accounts receivable increased to ¥155,540,334.11 from ¥136,965,314.50, representing a growth of approximately 13.5%[13]. - The company's inventory stood at ¥269,993,696.60, slightly up from ¥267,580,367.04, showing an increase of about 0.5%[13]. - The cash and cash equivalents decreased significantly to ¥54,469,157.35 from ¥95,672,928.04, a decline of approximately 43.1%[13]. Assets and Liabilities - Total assets at the end of the reporting period were ¥1,259,908,137.89, a decrease of 1.36% from the end of the previous year[6]. - As of March 31, 2024, the company's total assets amounted to ¥1,259,908,137.89, a decrease from ¥1,277,326,306.30 as of December 31, 2023, reflecting a decline of approximately 1.3%[13]. - Total liabilities decreased to ¥784,450,346.31 from ¥803,106,769.70, a reduction of approximately 2.9%[14]. - The company's equity attributable to shareholders rose to ¥471,013,163.47 from ¥469,268,077.30, reflecting an increase of about 0.4%[15]. - The company's long-term equity investments increased to ¥63,702,527.16 from ¥61,716,210.95, indicating a growth of about 3.2%[13]. - The deferred income tax assets increased to ¥45,335,851.61 from ¥38,631,552.55, representing a growth of approximately 17.4%[14]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 10,361[10]. - The company reported non-recurring gains of ¥1,191,795.47, after accounting for tax effects and minority interests[8]. - The decline in revenue was primarily due to a decrease in sales of protective equipment[8]. Financing Activities - The company reported a net cash outflow from investing activities of -¥14,359,402.21 in Q1 2024, compared to -¥21,819,338.85 in Q1 2023[21]. - The company raised ¥183,400,000.00 through financing activities in Q1 2024, compared to ¥197,615,100.00 in Q1 2023[21].

证券代码：603880 证券简称：ST 南卫 公告编号：2024-019 江苏南方卫材医药股份有限公司 收到上海证券交易所关于公司 2023 年度报告的 信息披露监管问询函的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 江苏南方卫材医药股份有限公司（以下简称公司）于 2024 年 4 月 19 日收到上 海证券交易所（以下简称上交所）出具的《关于江苏南方卫材医药股份有限公司 2023 年度报告的信息披露监管问询函》（上证公函【2024】0332 号）（以下简称 《问询函》），现将《问询函》具体内容公告如下： 2、年报及相关公告显示，公司报告期内计提固定资产减值，其中手套生产线 相关的设备计提减值 2825.21 万元。且年审会计师关键审计事项中提出，公司手套 生产线产能利用率低。请公司：（1）结合丁腈手套行业周期、公司产能利用率、 产销率，说明报告期内固定资产是否存在闲置情况，现有规模是否与公司生产经营 实际需求相匹配；（2）说明公司对手套产线产能利用率低已采取及拟采取的应对 措施；（3）结合前述情况，说明公司固定资产 ...

证券代码：603880 证券简称：ST 南卫 公告编号：2024-018 江苏南方卫材医药股份有限公司 2023 年年度股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 (一) 股东大会召开的时间：2024 年 4 月 19 日 (二) 股东大会召开的地点：江苏省常州市武进经济开发区果香路 1 号江苏南 方卫材医药股份有限公司二楼会议室 (三) 出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： 法有效。会议由公司董事会召集，公司董事长李平先生主持了会议。 (五) 公司董事、监事和董事会秘书的出席情况 二、 议案审议情况 审议结果：通过 | 表决情况： | | --- | 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 | 1、出席会议的股东和代理人人数 | 10 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 123,652,380 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | | | 份总数的比例（%） | 42. ...

法律意见书 南卫股份 &T PARTNERS 世纪同仁律师事务所 江 苏 世 纪 同 仁 律 师 事 务 所 关于江苏南方卫材医药股份有限公司 2023年年度股东大会的法律意见书 南 京 市 建 邺 区 贤 坤 路 江 岛 智 立 方 C 座 4 层 邮 编 : 210019 电 话： +86 25-83304480 传真： +86 25-83329335 法律意见书 南卫股份 江苏世纪同仁律师事务所 关于江苏南方卫材医药股份有限公司 2023 年年度股东大会的法律意见书 致:江苏南方卫材医药股份有限公司 法律意见书 根据《中华人民共和国公司法》《中华人民共和国证券法》和中国证监会《上 市公司股东大会规则》等法律、法规和规范性文件以及《公司章程》的规定,本 所受贵公司董事会的委托,指派本所律师出席贵公司 2023年年度股东大会,并 就本次股东大会的召集、召开程序、出席会议人员资格、召集人资格、表决程序 以及表决结果的合法有效性等事项出具法律意见。 为出具本法律意见书,本所律师对本次股东大会所涉及的有关事项进行了审 查,查阅了本所律师认为出具法律意见所必须查阅的文件,并对有关问题进行了 必要的核查和验证。 本所 ...

江苏南方卫材医药股份有限公司 2023 年年度股东大会 会议资料 江苏南方卫材医药股份有限公司 2023 年年度股东大会会议资料 股票代码：603880 2024 年 4 月 19 日 23 江苏南方卫材医药股份有限公司 2023年年度股东大会会议资料 目 录 | 年年度股东大会会议须知 3 | | | 2023 | | --- | --- | --- | --- | | 年年度股东大会会议议程 5 | | | 2023 | | 年年度股东大会会议议案 7 | | | 2023 | | 议案一：《公司 年年度报告及其摘要》 7 | 2023 | | | | 议案二：《2023 年度董事会工作报告》 8 | | | | | 议案三：《2023 年度监事会工作报告》 13 | | | | | 议案四：《2023 年度财务决算报告》 18 | | | | | 议案五：《公司 年度利润分配预案》 23 | 2023 | | | | 议案六：《关于 年度计提资产减值准备的议案》 24 | 2023 | | | | 议案七：《关于公司 2024 年度向银行及其他金融机构申请综合授信额度及提 | | | | | 供担保的议 ...

Financial Performance - The company's total revenue for 2023 was CNY 600,095,343.68, representing a 10.03% increase compared to CNY 545,369,151.61 in 2022[25]. - The net profit attributable to shareholders for 2023 was a loss of CNY 147,417,266.38, a significant decline from a loss of CNY 14,648,702.48 in 2022, marking a 906.35% increase in losses[25]. - The cash flow from operating activities for 2023 was CNY 15,509,532.60, down 50.41% from CNY 31,276,448.73 in 2022[25]. - The total assets at the end of 2023 were CNY 1,277,326,306.30, a decrease of 12.36% from CNY 1,457,445,778.40 at the end of 2022[26]. - The net assets attributable to shareholders decreased by 23.90% to CNY 469,268,077.30 from CNY 616,660,064.22 in 2022[26]. - The company achieved operating revenue of 600.10 million yuan in 2023, an increase of 5.47 million yuan compared to the previous year[34]. - The net profit attributable to shareholders of the parent company was -147.42 million yuan, a decrease of 132.77 million yuan year-on-year[34]. - Basic and diluted earnings per share were both -0.51 yuan, representing a 920% decrease compared to -0.05 yuan in 2022[27]. - The weighted average return on equity was -27.15%, down from -2.30% in the previous year, indicating a significant decline in profitability[27]. - The company reported a significant increase in financial expenses, up 69.69% to 21,768,559.33 CNY, primarily due to currency fluctuations and interest on short-term loans[61]. - Operating costs rose to 544,429,465.19 CNY, reflecting a 15.06% increase due to higher revenue[61]. Governance and Compliance - The company plans not to distribute profits for 2023 due to the negative net profit, aiming to ensure stable operations and long-term shareholder interests[6]. - The company has not reported any significant operational risks that could impact its business during the reporting period[9]. - The company has not engaged in any non-operational fund occupation by controlling shareholders or related parties[8]. - The company has not provided any guarantees in violation of regulatory decision-making procedures[8]. - The company’s future plans and strategies are subject to risks and do not constitute a commitment to investors[7]. - The company held 3 shareholder meetings and 6 board meetings during the reporting period to strengthen corporate governance[34]. - The company plans to enhance its internal control management system and improve governance structure in line with regulatory requirements[34]. - The company has established a sound governance structure, complying with relevant laws and regulations to support its sustainable development[131]. - The company has revised its independent director work system to enhance governance practices[140]. - The company has implemented a comprehensive information disclosure policy, ensuring timely and accurate communication with stakeholders[138]. Research and Development - R&D expenses for the reporting period amounted to RMB 28.18 million, an increase of 1.64% compared to the previous year, focusing on transdermal drug delivery technology and product improvement[35]. - The company holds 26 Class I medical device filings, 19 Class II medical device registrations, and 3 drug registration certificates, with main products certified by both FDA and TÜV SÜD[36]. - The company has established a research and development center in collaboration with Zhejiang University, focusing on new transdermal formulations and technologies, including gel and microneedle formulations[53]. - The company has obtained one invention patent and applied for another during the reporting period, indicating ongoing innovation in product development[53]. - The company has 11 invention patents, 41 utility models, and 9 design patents, enhancing its competitive edge in technology development[35]. - The company is focusing on optimizing the production process of latex gloves to improve quality and address issues related to latex sedimentation during the dipping process[91]. - The company intends to strengthen its R&D capabilities by developing new transdermal formulations, medical dressings, and disposable protective products[121]. Market and Product Development - The company has focused on product structure adjustments and regional layout to promote healthy business development in response to market demands[34]. - The company has established a leading position in the domestic market for wound dressings, leveraging ODM business models and increasing direct sales[42]. - The company is involved in the research and development of various medical devices and sports products, aiming to expand its product offerings[109]. - The company is exploring opportunities in the international market for its medical and sports products, aiming for global expansion[109]. - The company plans to explore more emergency product developments for family, traffic accidents, and natural disasters in the future[92]. - The company has introduced 9 new domestic medical device products during the reporting period, with a total of 26 Class I medical device filings and 19 Class II medical device registrations[94]. Financial Management and Strategy - The company plans to enhance its financial management by reducing financial costs and improving asset-liability ratios while optimizing resource allocation[119]. - The company aims to integrate its R&D efforts with market needs to improve innovation capabilities and product offerings[121]. - The company plans to control production costs and expenses, striving for profitability while seeking new profit growth points[116]. - The company plans to use the remaining raised funds to permanently supplement working capital[151]. - The company has a cash dividend policy that mandates a minimum of 25% of distributable profits to be distributed as cash dividends when conditions allow[169]. - The company plans to implement a differentiated cash dividend policy, with a minimum of 80% cash distribution for mature stages without major capital expenditures[169]. Environmental and Social Responsibility - The company reported an investment of 2.672 million yuan in environmental protection during the reporting period[180]. - The company has committed to maintaining stock lock-up periods for its executives and shareholders, with specific conditions for share transfers[188]. - The company operates 2 gas boilers using 1.5 million cubic meters of natural gas annually, with emissions meeting the GB13271-2014 standards for pollutants[181]. - Noise levels at the factory comply with the GB12348-2008 standards, with daytime limits set at ≤65dB(A) and nighttime limits at ≤55dB(A)[183]. - Solid waste is managed through a standardized disposal process, with hazardous waste handled by qualified third-party companies[184]. - The company has established an emergency response plan for environmental incidents, enhancing its capability to manage such events[184]. Risks and Challenges - The company recognizes the risk of intensified market competition in the medical device industry, particularly in the low-end market segment[124]. - The company is aware of potential risks from changes in industry policies that could impact its operations[123]. - The company faced product liability risks due to the nature of its medical products, which could impact its reputation and operational capacity[128]. - The company is exposed to distributor management risks, which could lead to sales declines if distributors face operational issues[129]. Shareholder Relations - The company emphasizes investor relations, utilizing multiple channels to engage with investors and protect their interests[137]. - The company actively engages with minority shareholders to gather their opinions on profit distribution matters[170]. - The total pre-tax compensation for the board members amounted to 248.95 million CNY for the reporting period[142]. - The company has not reported any compensation received from related parties by its board members[142].

江苏南方卫材医药股份有限公司 2023 年度独立董事述职报告 2023 年度,本人作为江苏南方卫材医药股份有限公司(以下简称"公司" "上市公司""南卫股份")的独立董事,严格按照《公司法》《证券法》《上 市公司独立董事管理办法》《上海证券交易所股票上市规则》等相关法律法规及 业务规则的要求,积极履行独立董事职责,独立、勤勉、负责地行使职权,按时 参加公司 2023年董事会及相关会议,发挥独立董事的作用。现就 2023年度履职 情况报告如下: 二、独立董事年度履职情况 一、独立董事基本情况 许敏先生,1964年1月出生,中国国籍,无境外居留权,博士,三级教授, 硕士生导师,北京大学工商管理博士后。现任南京工业大学"协同创新与产业发 展研究中心"主任、"公司财务与技术创新研究所"所长。担任中国会计学会高 等工科院校分会副会长,江苏省会计学会常务理事,江苏省财政厅"管理会计咨 询专家",《南京工业大学学报(社会科学版)》编辑委员会委员等。曾任南京 工业学经济与管理学院副院长、南京工业大学计划财务部部长。主持4项国家级 项目、5 项省级项目及 3 项厅级项目,获得第十二届江苏省哲学社会科学优秀成 果奖二等奖(负责人 ...